These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18592354)

  • 1. Ultrasound assisted engineering of lactose crystals.
    Dhumal RS; Biradar SV; Paradkar AR; York P
    Pharm Res; 2008 Dec; 25(12):2835-44. PubMed ID: 18592354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of carrier morphology on drug delivery by dry powder inhalers.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 2000 Apr; 200(1):93-106. PubMed ID: 10845690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.
    Larhrib H; Martin GP; Prime D; Marriott C
    Eur J Pharm Sci; 2003 Jul; 19(4):211-21. PubMed ID: 12885385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of carrier and drug morphology on drug delivery from dry powder formulations.
    Larhrib H; Martin GP; Marriott C; Prime D
    Int J Pharm; 2003 May; 257(1-2):283-96. PubMed ID: 12711183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery.
    Dhumal RS; Biradar SV; Paradkar AR; York P
    Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate.
    Ming Zeng X ; Martin GP; Marriott C; Pritchard J
    Eur J Pharm Biopharm; 2001 Jan; 51(1):55-62. PubMed ID: 11154904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid crystalline phase as a probe for crystal engineering of lactose: carrier for pulmonary drug delivery.
    Patil SS; Mahadik KR; Paradkar AR
    Eur J Pharm Sci; 2015 Feb; 68():43-50. PubMed ID: 25460546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
    Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Pharmacol; 2000 Oct; 52(10):1211-21. PubMed ID: 11092565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.